AA
FPRX

Ancora Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Ancora Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,000
Closed -$134K – 631
2019
Q1 		$134K Hold
10,000
– – 0.01% 578
2018
Q4 		$93K Hold
10,000
– – ﹤0.01% 583
2018
Q3 		$139K Hold
10,000
– – 0.01% 697
2018
Q2 		$158K Buy
+10,000
New +$175K 0.01% 662

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ancora Advisors's FPRX Position: Q2 2019 in Review

Ancora Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2019, closing a stake of 10,000 shares — an estimated $134K sold.

Ancora Advisors first reported a position in FPRX in Q2 2018 and held it in 4 quarters. The position peaked at $158K in Q2 2018. 114 funds tracked by Wall St. Rank hold FPRX as of Q2 2019.

  • Ancora Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Ancora Advisors sold 10,000 Five Prime Therapeutics, Inc. shares in Q2 2019, an estimated $134K.
  • Ancora Advisors first reported a position in Five Prime Therapeutics, Inc. in Q2 2018 and held it in 4 quarters.
  • Ancora Advisors's Five Prime Therapeutics, Inc. position peaked at $158K in Q2 2018.
  • 114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2019.

Based on Ancora Advisors's 13F filing for Q2 2019, filed 12 Aug 2019.